SCT 650A
Alternative Names: SCT-650ALatest Information Update: 28 Mar 2025
At a glance
- Originator Sinocelltech
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Interleukin 17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ankylosing spondylitis; Psoriasis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Ankylosing-spondylitis in China (Parenteral)
- 28 Mar 2025 No recent reports of development identified for preclinical development in Psoriasis in China (Parenteral)
- 22 Feb 2021 Preclinical trials in Ankylosing spondylitis in China (unspecified route) before February 2021 (SinoCellTech pipeline, February 2021)